Concepta PLC Concepta to supply myLotus® to Walgreens Boots (5654S)
March 12 2019 - 3:02AM
UK Regulatory
TIDMCPT
RNS Number : 5654S
Concepta PLC
12 March 2019
Concepta PLC
12 March 2019
Concepta to supply myLotus(R) to Walgreens Boots
Concepta Plc (AIM: CPT), the innovative UK personalised
healthcare company and developer of the proprietary self-test
platform ("myLotus(R)") and suite of emerging test products
targeting the mobile health market is pleased to announce it has
agreed to supply the myLotus(R) product to Walgreens Boots Alliance
(WBA) for women's fertility and hormone testing.
myLotus(R) the revolutionary home based, self-test product was
launched in November 2018 with early 'trying to conceive' users
providing personal video feedback and testimonials on their
menstrual cycle hormone changes and hormone patterns ('signatures')
enabling women to better understand their menstrual cycle and
fertility journey (www.mylotus.com).
The supply agreement represents the first commercial partnership
forming part of the Company's EU roll-out plans. myLotus(R)
recently received CE-Mark certification and the agreement allows
the Company to extend its UK relationship with 'Boots the Chemist'
to other Walgreens Boots Alliance partners across EU markets
(CE-Mark territories).
myLotus(R) empowers women to self-test their personalised
hormone levels and identify their optimal fertile days thereby
improving their chances of naturally getting pregnant. myLotus(R)
enables women to monitor their fertile phase as part of their
menstrual cycle and is the only home test to 'quantitatively'
measure hormone levels and the 'rate-of-change' of these levels
preceding ovulation to help aid a natural conception. Users
measure, record and track their hormone levels and follow their
fertility journey in an accompanying free downloadable app
available in iOS and Android formats via the www.mylotus.com
website.
myLotus(R) is available to women who are planning to start a
family or for those who have previously struggled to naturally
conceive, enabling couples an alternative prior to considering more
costly IVF treatment. The Company expects to release further
hormone health and wellbeing tests to complement its fertility
offering later this year.
Matthew Walls, Chairman said: "We are delighted to work with
such a respected British high-street brand and retailer and look
forward to supplying myLotus(R) to Boots the Chemist to help
improve the chances of a natural pregnancy. We are now preparing
our EU market roll-out plans and will update the market in due
course"
Enquiries:
The Company
Company: www.conceptaplc.com, Product: www.mylotus.com
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Concepta Plc:
About Concepta Plc: Concepta Plc is an AIM-quoted pioneering UK
healthcare company that has developed a proprietary product,
myLotus(R), targeted at the personalised mobile health market with
a primary focus on hormone testing and increasing a woman's chances
of naturally getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2019.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAKDAFLFNEEF
(END) Dow Jones Newswires
March 12, 2019 03:02 ET (07:02 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024